Nyhet -

Get ahead with the right development tools and support from Prevas

Prevas can take their customers’ projects further than ever before. This is primarily due to dedicated up-scaling of the company’s activities involving Life Science. There is also a brand new strategy in place, clearly defining what the Life Science industry customers need and where Prevas can make a difference.

Prevas works closely with customers in developing projects within medical technology, pharmaceuticals, biotechnology and even within the area of combined products. Within all the mentioned areas, Prevas consultants’ characteristic expertise in industrial design can effectively be combined with know-how in areas specifically important to players in the Life Science industry, such as QA, RA, product and/or prototype construction, testing, clinical development and trials, and so on.

“We have extensive experience in developing complete products in-house. Customers often come to us with an idea or an innovation that has not yet been verified. We help them through all stages, from the initial verification process of innovations, and all the way to a complete and approved product. Furthermore, we can put the product into production and help with CE certification and the whole process around that as well”, explains Robert Tönhardt, Life Science Director at Prevas.

The Prevas approach

Prevas employs a very flexible approach to customer projects overall, offering everything in the range of a few consultancy hours to full in-house projects over the course of several years. Project sizes range from one to over 50 dedicated developers at a time. And most importantly, Prevas has the flexibility to accommodate all types of projects, in any Life Science-related area. So what types of projects are most common?

“Lately many customers have asked for help in the specification of the regulatory strategy, as well as with the process of classifying the safety-level of their software and help to set up QMS. We have also seen some extra demand on our ISO13485-certified design and construction facility for developing complete medtech products”, says Robert Tönhardt, and continues:

“To become better in supporting our customers we have to some extent re-structured Prevas’ Life Science department when it comes to our offer and strategy. In that process, we have divided Life Science in several different areas or divisions, such as one separate division for the development of pharmaceuticals and one for the development of medical technology products, for example”.

The latest developments

The result in getting a more precise structure of Prevas in Life Science, is that the company can provide much better and more tailored services to its customers. The latest developments within the Prevas Life Science offer consist of the addition of services in industrial design and a whole new expert team set up in cyber security.

Prevas has a strong presence in the Medicon Valley region, with over 30 consultants dedicated to Life Science projects employed in Denmark, and almost as many consultants in the Lund-Malmö area. The number of consultants in Life Science is likely to increase as Prevas has a clear strategy when it comes to the development of a strong presence in the region, specifically focusing on QA and RA for the time being.

With active memberships in key networks and incubators such as Medicon Village and the SmiLe incubator in Lund, Medicoindustrien in Denmark and the Danish Life Science Cluster, Prevas has the ability to attract talents to facilitate the company’s goal of becoming a preferred partner in the development of entire projects; from idea to certified product.

Relaterade länkar

Ämnen

  • Ekonomi, finans

Kategorier

  • medicon valley life science

Regioner

  • Skåne

Kontakter

Relaterad media

Relaterat innehåll

  • Cancer treatment developed in Sweden may be a game-changer

    Cantargia has managed to do what so many other companies in oncology treatment development have failed to do. In just under ten years, Cantargia has been able to advance from an academic environment to a listed company with several ongoing clinical trials. Thus, Cantargia dispels the myth that new treatments in oncology take decades to develop from the initial discovery.
    Cantargia’s lead drug

  • Active Biotech develops first-in-class targets

    Active Biotech is aa company that develops pharmaceutical products within medical areas where the immune defence is significant, including cancer and inflammatory diseases. All of Active Biotech’s leads are first-in-class, unique targets that open completely new opportunities.
    Active Biotech is based in Lund, Sweden, and was formed in 1998 as a spin-off from Pharmacia & Upjohn. Active Biot

  • Øresunddirekt provides guidance through the jungle of international work regulations

    The aim of the advisory service center Øresunddirekt is to bridge the gap between citizens, businesses, and authorities on both sides of the Oresund strait. This is done by providing an accessible platform for information gathering, sharing and updating, and making the information available and accessible to people and companies with interest in working across the border.

  • Major investment in bioanalytical services

    The Uppsala-based company, Mercodia, born out of a vibrant Life Science environment with a solid, long-standing reputation globally and especially throughout the Nordics as an immunoassay manufacturer and supplier, is now focusing on delivering bioanalytical services. The bioanalytical services are mainly directed toward pharma- and biotech companies and CROs in Europe and North America.

  • The Holy Grail to promote better public health and wellbeing

    Lundoch Diagnostics was founded by Dr Yang De Marinis in 2020. The company is widely known for the development and launch of the world’s first and only blood test technology to detect diabetes risk many years before diagnosis or any symptoms appear. This is the Holy Grail to promote better public health and wellbeing.

Fyll i din epostadress för att följa Affärstidningen Näringsliv

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa Affärstidningen Näringsliv.

Okej